Vertex Pharma (VRTX) Tops Q3 EPS by 23c, provides guidance
Tweet
Share
E-mail
Get Alerts VRTX Hot Sheet
Price: $491.34 +2.32%
Revenue Growth %: +8.4%
Financial Fact:
Loss before provision for income taxes: -39.03M
Today's EPS Names:
CGEH, NAKA, APOG, More
Revenue Growth %: +8.4%
Financial Fact:
Loss before provision for income taxes: -39.03M
Today's EPS Names:
CGEH, NAKA, APOG, More
Join SI Premium – FREE
Vertex Pharma (NASDAQ: VRTX) reported Q3 EPS of $4.80, $0.23 better than the analyst estimate of $4.57. Revenue for the quarter came in at $3.08 billion versus the consensus estimate of $3.05 billion.
GUIDANCE:
Vertex Pharma sees FY2025 revenue of $11.9-12 billion, versus the consensus of $12.002 billion.
For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gulfport Energy and Mobility Global to join S&P SmallCap 600
- Select Medical stockholders approve buyout by insider-led consortium
- TNL Mediagene faces Nasdaq delisting over bid price and equity rules
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
